Home › Funds › MPM BioImpact LLC › PVLA
MPM BioImpact LLC position in PVLA
PALVELLA THERAPEUTICS INC NEW COM · Health Care
MPM BioImpact LLC reported holding 204,027 shares of PVLA (PALVELLA THERAPEUTICS INC NEW COM) in its Q2 2026 13F filing — a position valued at US$31.2M, representing 1.90% of its reported portfolio and ranking #20 among its reported holdings. MPM BioImpact LLC has disclosed PVLA holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's PVLA position evolved
MPM BioImpact LLC first disclosed a stake in PVLA in Q3 2025 at 67,423 shares (US$4.2M). The position peaked in Q2 2026 at 204,027 shares, worth US$31.2M. Across 4 filings, MPM BioImpact LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 204,027 shares valued at US$31.2M — a reduction of -2,377 shares quarter over quarter.. Notable position changes include a 205% increase in Q4 2025 (shares rose 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 67.42K | $4.23M | New |
| Q4 2025 | 205.75K | $21.54M | Add |
| Q1 2026 | 206.40K | $25.73M | Hold |
| Q2 2026 | 204.03K | $31.18M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PVLA and 13F data
PVLA (PALVELLA THERAPEUTICS INC NEW COM) is a Health Care company. 90 other funds we track also report a position in PVLA — the largest reported positions include MONTANOVA CAPITAL, LLC (US$173.5M), Frazier Life Sciences Management, L.P. (US$134.8M), First Light Asset Management, LLC (US$118.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PVLA
- MONTANOVA CAPITAL, LLC 1.14M sh · $173.51M · Q2 2026
- Frazier Life Sciences Management, L.P. 882.40K sh · $134.85M · Q2 2026
- First Light Asset Management, LLC 771.90K sh · $117.96M · Q2 2026
- BVF INC/IL 672.79K sh · $102.82M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 478.83K sh · $73.18M · Q2 2026
- Siren, L.L.C. 257.49K sh · $39.35M · Q2 2026
- EMERALD ADVISERS, LLC 229.49K sh · $35.07M · Q2 2026
- First Turn Management, LLC 156.45K sh · $23.91M · Q2 2026
- Bellevue Group AG 155.00K sh · $23.69M · Q2 2026
- NEXTBio Capital Management LP 89.91K sh · $13.74M · Q2 2026
- Clio Asset Management LLC 86.01K sh · $11.86M · Q3 2026
- Avidity Partners Management LP 70.00K sh · $10.70M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held PVLA?
MPM BioImpact LLC has disclosed PVLA holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is MPM BioImpact LLC's current position in PVLA?
As of Q2 2026, MPM BioImpact LLC holds 204.03K shares of PVLA (PALVELLA THERAPEUTICS INC NEW COM), valued at $31.18M, representing 1.90% of its reported portfolio and ranking #20.
Has MPM BioImpact LLC been buying or selling PVLA?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in PVLA. The position peaked in Q2 2026 at 204.03K shares.
Which other funds hold PVLA?
Other major institutional holders of PVLA include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., First Light Asset Management, LLC, among 90 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.